Acer Therapeutics Inc. (ACER) financial statements (2020 and earlier)

Company profile

Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.)
NEWTON, MA 02458
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1216233242468
Cash and cash equivalents1216233242468
Prepaid expense     11
Other undisclosed current assets11111  
Total current assets:1317243343479
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill)8888888
Goodwill8888888
Other noncurrent assets1110000
Other undisclosed noncurrent assets0000000
Total noncurrent assets:9898888
TOTAL ASSETS:21263341515517
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3253623
Accounts payable1020111
Accrued liabilities2233522
Other liabilities0000   
Total current liabilities:3253623
Noncurrent Liabilities
Liabilities, other than long-term debt0000   
Other liabilities0000   
Total noncurrent liabilities:0000   
Total liabilities:3353623
Stockholders' equity
Stockholders' equity attributable to parent18232838455314
Common stock0000000
Additional paid in capital95949393929148
Accumulated deficit(76)(71)(66)(55)(47)(38)(34)
Total stockholders' equity:18232838455314
TOTAL LIABILITIES AND EQUITY:21263341515517

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(5)(5)(11)(8)(9)(4)(5)
Operating loss:(5)(5)(11)(8)(9)(4)(5)
Nonoperating income0000000
Investment income, nonoperating00     
Foreign currency transaction gain (loss), before tax(0)0     
Other nonoperating income  00000
Net loss available to common stockholders, diluted:(5)(5)(11)(8)(8)(4)(5)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(5)(5)(11)(8)(8)(4)(5)
Comprehensive loss, net of tax, attributable to parent:(5)(5)(11)(8)(8)(4)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: